ADC Therapeutics S.A.
ADCT · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $70,837 | $69,558 | $209,908 | $33,917 |
| % Growth | 1.8% | -66.9% | 518.9% | – |
| Cost of Goods Sold | $5,949 | $2,529 | $3,301 | $1,393 |
| Gross Profit | $64,888 | $67,029 | $206,607 | $32,524 |
| % Margin | 91.6% | 96.4% | 98.4% | 95.9% |
| R&D Expenses | $109,633 | $127,127 | $186,457 | $158,002 |
| G&A Expenses | $64,467 | $72,882 | $107,742 | $71,462 |
| SG&A Expenses | $85,909 | $105,888 | $143,494 | $136,242 |
| Sales & Mktg Exp. | $21,442 | $33,006 | $35,752 | $64,780 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $195,542 | $233,015 | $329,951 | $294,244 |
| Operating Income | -$130,654 | -$165,986 | -$123,344 | -$261,720 |
| % Margin | -184.4% | -238.6% | -58.8% | -771.6% |
| Other Income/Exp. Net | -$27,026 | -$34,961 | -$33,557 | $10,215 |
| Pre-Tax Income | -$157,680 | -$200,947 | -$156,901 | -$251,505 |
| Tax Expense | $166 | $39,106 | $227 | -$21,479 |
| Net Income | -$157,846 | -$240,053 | -$157,128 | -$230,026 |
| % Margin | -222.8% | -345.1% | -74.9% | -678.2% |
| EPS | -1.62 | -2.94 | -1.99 | -3 |
| % Growth | 44.9% | -47.7% | 33.7% | – |
| EPS Diluted | -1.62 | -2.94 | -1.99 | -3 |
| Weighted Avg Shares Out | 97,160 | 81,712 | 78,153 | 76,748 |
| Weighted Avg Shares Out Dil | 97,160 | 81,712 | 78,153 | 76,748 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12,272 | $10,540 | $2,568 | $66 |
| Interest Expense | $50,211 | $46,325 | $36,731 | $18,340 |
| Depreciation & Amortization | $3,276 | $3,267 | $2,388 | $2,630 |
| EBITDA | -$102,649 | -$145,827 | -$107,698 | -$230,535 |
| % Margin | -144.9% | -209.6% | -51.3% | -679.7% |